Preclinical Modeling of Myelodysplastic Syndromes

Overview

Journal Leukemia

Specialties Hematology
Oncology

Date 2017 Jul 1

PMID 28663577

Citations 25

Authors

K Rouault-Pierre

S A Mian

M Goulard

A Abarrategi

A Di Tulio

A E Smith

A Mohamedali

S Best

A-M Nloga

A G Kulasekararaj

L Ades

C Chomienne

P Fenaux

C Dosquet

G J Mufti

D Bonnet

Affiliations

Soon will be listed here.

Abstract

Myelodysplastic syndromes (MDS) represent a heterogeneous group of hematological clonal disorders. Here, we have tested the bone marrow (BM) cells from 38 MDS patients covering all risk groups in two immunodeficient mouse models: NSG and NSG-S. Our data show comparable level of engraftment in both models. The level of engraftment was patient specific with no correlation to any specific MDS risk group. Furthermore, the co-injection of mesenchymal stromal cells (MSCs) did not improve the level of engraftment. Finally, we have developed an in vitro two-dimensional co-culture system as an alternative tool to in vivo. Using our in vitro system, we have been able to co-culture CD34 cells from MDS patient BM on auto- and/or allogeneic MSCs over 4 weeks with a fold expansion of up to 600 times. More importantly, these expanded cells conserved their MDS clonal architecture as well as genomic integrity.

Citing Articles

Influence of donor-recipient sex on engraftment of normal and leukemia stem cells in xenotransplantation.

Mian S, Ariza-McNaughton L, Anjos-Afonso F, Guring R, Jackson S, Kizilors A Hemasphere. 2024; 8(5):e80.

PMID: 38774656 PMC: 11107397. DOI: 10.1002/hem3.80.

The evolution of preclinical models for myelodysplastic neoplasms.

Mina A, Pavletic S, Aplan P Leukemia. 2024; 38(4):683-691.

PMID: 38396286 PMC: 10997513. DOI: 10.1038/s41375-024-02181-2.

Modeling the Tumor Microenvironment and Cancer Immunotherapy in Next-Generation Humanized Mice.

Chen A, Neuwirth I, Herndler-Brandstetter D Cancers (Basel). 2023; 15(11).

PMID: 37296949 PMC: 10251926. DOI: 10.3390/cancers15112989.

Vitamin B5 and succinyl-CoA improve ineffective erythropoiesis in -mutated myelodysplasia.

Mian S, Philippe C, Maniati E, Protopapa P, Bergot T, Piganeau M Sci Transl Med. 2023; 15(685):eabn5135.

PMID: 36857430 PMC: 7614516. DOI: 10.1126/scitranslmed.abn5135.

Selective inhibition of MCL1 overcomes venetoclax resistance in a murine model of myelodysplastic syndromes.

Fischer M, Song Y, Arrate M, Gbyli R, Villaume M, Smith B Haematologica. 2022; 108(2):522-531.

PMID: 35979721 PMC: 9890032. DOI: 10.3324/haematol.2022.280631.

References

Mian S, Rouault-Pierre K, Smith A, Seidl T, Pizzitola I, Kizilors A . SF3B1 mutant MDS-initiating cells may arise from the haematopoietic stem cell compartment. Nat Commun. 2015; 6:10004. PMC: 4686651. DOI: 10.1038/ncomms10004. View

Abarrategi A, Foster K, Hamilton A, Mian S, Passaro D, Gribben J . Versatile humanized niche model enables study of normal and malignant human hematopoiesis. J Clin Invest. 2017; 127(2):543-548. PMC: 5272182. DOI: 10.1172/JCI89364. View

Rouault-Pierre K, Smith A, Mian S, Pizzitola I, Kulasekararaj A, Mufti G . Myelodysplastic syndrome can propagate from the multipotent progenitor compartment. Haematologica. 2016; 102(1):e7-e10. PMC: 5210239. DOI: 10.3324/haematol.2016.152520. View

Yoshida K, Sanada M, Shiraishi Y, Nowak D, Nagata Y, Yamamoto R . Frequent pathway mutations of splicing machinery in myelodysplasia. Nature. 2011; 478(7367):64-9. DOI: 10.1038/nature10496. View

Gangat N, Patnaik M, Tefferi A . Myelodysplastic syndromes: Contemporary review and how we treat. Am J Hematol. 2016; 91(1):76-89. DOI: 10.1002/ajh.24253. View

Mian S, Smith A, Kulasekararaj A, Kizilors A, Mohamedali A, Lea N . Spliceosome mutations exhibit specific associations with epigenetic modifiers and proto-oncogenes mutated in myelodysplastic syndrome. Haematologica. 2013; 98(7):1058-66. PMC: 3696609. DOI: 10.3324/haematol.2012.075325. View

Wunderlich M, Brooks R, Panchal R, Rhyasen G, Danet-Desnoyers G, Mulloy J . OKT3 prevents xenogeneic GVHD and allows reliable xenograft initiation from unfractionated human hematopoietic tissues. Blood. 2014; 123(24):e134-44. PMC: 4055932. DOI: 10.1182/blood-2014-02-556340. View

Geyh S, Oz S, Cadeddu R, Frobel J, Bruckner B, Kundgen A . Insufficient stromal support in MDS results from molecular and functional deficits of mesenchymal stromal cells. Leukemia. 2013; 27(9):1841-51. DOI: 10.1038/leu.2013.193. View

Haferlach T, Nagata Y, Grossmann V, Okuno Y, Bacher U, Nagae G . Landscape of genetic lesions in 944 patients with myelodysplastic syndromes. Leukemia. 2013; 28(2):241-7. PMC: 3918868. DOI: 10.1038/leu.2013.336. View

10.

Medyouf H, Mossner M, Jann J, Nolte F, Raffel S, Herrmann C . Myelodysplastic cells in patients reprogram mesenchymal stromal cells to establish a transplantable stem cell niche disease unit. Cell Stem Cell. 2014; 14(6):824-37. DOI: 10.1016/j.stem.2014.02.014. View

11.

Greenberg P, Tuechler H, Schanz J, Sanz G, Garcia-Manero G, Sole F . Revised international prognostic scoring system for myelodysplastic syndromes. Blood. 2012; 120(12):2454-65. PMC: 4425443. DOI: 10.1182/blood-2012-03-420489. View

12.

Reinisch A, Thomas D, Corces M, Zhang X, Gratzinger D, Hong W . A humanized bone marrow ossicle xenotransplantation model enables improved engraftment of healthy and leukemic human hematopoietic cells. Nat Med. 2016; 22(7):812-21. PMC: 5549556. DOI: 10.1038/nm.4103. View

13.

Woll P, Kjallquist U, Chowdhury O, Doolittle H, Wedge D, Thongjuea S . Myelodysplastic syndromes are propagated by rare and distinct human cancer stem cells in vivo. Cancer Cell. 2014; 25(6):794-808. DOI: 10.1016/j.ccr.2014.03.036. View

14.

Mufti G, Bennett J, Goasguen J, Bain B, Baumann I, Brunning R . Diagnosis and classification of myelodysplastic syndrome: International Working Group on Morphology of myelodysplastic syndrome (IWGM-MDS) consensus proposals for the definition and enumeration of myeloblasts and ring sideroblasts. Haematologica. 2008; 93(11):1712-7. DOI: 10.3324/haematol.13405. View

15.

Papaemmanuil E, Cazzola M, Boultwood J, Malcovati L, Vyas P, Bowen D . Somatic SF3B1 mutation in myelodysplasia with ring sideroblasts. N Engl J Med. 2011; 365(15):1384-95. PMC: 3322589. DOI: 10.1056/NEJMoa1103283. View

16.

Li X, Deeg H . Murine xenogeneic models of myelodysplastic syndrome: an essential role for stroma cells. Exp Hematol. 2013; 42(1):4-10. PMC: 4053244. DOI: 10.1016/j.exphem.2013.10.002. View